Loading…

Potential for brain accessibility and analysis of stability of selected flavonoids in relation to neuroprotection in vitro

Abstract Natural food sources constitute a promising source of new compounds with neuroprotective properties, once they have the ability to reach the brain. Our aim was to evaluate the brain accessibility of quercetin, epigallocatechin gallate (EGCG) and cyanidin-3-glucoside (C3G) in relation to the...

Full description

Saved in:
Bibliographic Details
Published in:Brain research 2016-11, Vol.1651, p.17-26
Main Authors: Pogačnik, Lea, Pirc, Katja, Palmela, Inês, Skrt, Mihaela, Kwang, Kim S, Brites, Dora, Brito, Maria Alexandra, Ulrih, Nataša Poklar, Silva, Rui F.M
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c456t-61693047c5f4aff0ce49062ceab377a11f13e4bf64c88e2b294d0bf598ce74323
cites cdi_FETCH-LOGICAL-c456t-61693047c5f4aff0ce49062ceab377a11f13e4bf64c88e2b294d0bf598ce74323
container_end_page 26
container_issue
container_start_page 17
container_title Brain research
container_volume 1651
creator Pogačnik, Lea
Pirc, Katja
Palmela, Inês
Skrt, Mihaela
Kwang, Kim S
Brites, Dora
Brito, Maria Alexandra
Ulrih, Nataša Poklar
Silva, Rui F.M
description Abstract Natural food sources constitute a promising source of new compounds with neuroprotective properties, once they have the ability to reach the brain. Our aim was to evaluate the brain accessibility of quercetin, epigallocatechin gallate (EGCG) and cyanidin-3-glucoside (C3G) in relation to their neuroprotective capability. Primary cortical neuron cultures were exposed to oxidative insult in the absence and presence of the selected compounds, and neuroprotection was assessed through evaluation of apoptotic-like and necrotic-like cell death. The brain accessibility of selected compounds was assessed using an optimised human blood-brain barrier model. The blood-brain barrier model was crossed rapidly by EGCG and more slowly by C3G, but not by quercetin. EGCG protected against oxidation-induced neuronal necrotic-like cell death by ~40%, and apoptosis by ~30%. Both quercetin and C3G were less effective, since only the lowest quercetin concentration was protective, and C3G only prevented necrosis by ~37%. Quercetin, EGCG and C3G effectively inhibited α-synuclein fibrillation over the relevant timescale applied here. Overall, EGCG seems to be the most promising neuroprotective compound. Thus, inclusion of this polyphenol in the diet might provide an affordable means to reduce the impact of neurodegenerative diseases.
doi_str_mv 10.1016/j.brainres.2016.09.020
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1837295520</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0006899316306485</els_id><sourcerecordid>1837295520</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-61693047c5f4aff0ce49062ceab377a11f13e4bf64c88e2b294d0bf598ce74323</originalsourceid><addsrcrecordid>eNqFUU2PFCEQJUbjjqt_YcPRy7QFdNPNxWg260eyiSbqmdB0kTAyzQr0JOOvl56Z9eDFAyFFvXqPeo-QGwYNAybf7JoxGT8nzA2vdQOqAQ5PyIYNPd9K3sJTsgEAuR2UElfkRc67Wgqh4Dm54r0UamCwIb-_xoJz8SZQFxM9kVJjLebsRx98OVIzT_WYcMw-0-hoLubSWQsMaAtO1AVziHP0U6aVIWEwxceZlkhnXFJ8SFXHnp5q--BLii_JM2dCxleX-5r8-HD3_fbT9v7Lx8-37--3tu1k2UomlYC2t51rjXNgsVUguUUzir43jDkmsB2dbO0wIB-5aicYXacGi30ruLgmr8-89Q-_FsxF7322GIKZMS5Zs0H0XHUdhwqVZ6hNMeeETj8kvzfpqBno1Xe904--69V3DUrDafDmorGMe5z-jj0aXQHvzgCsmx48Jp2tx9ni5FP1RU_R_1_j7T8UNvjZWxN-4hHzLi6pplT30Zlr0N_W9NfwmRQg26ETfwAlyq9C</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1837295520</pqid></control><display><type>article</type><title>Potential for brain accessibility and analysis of stability of selected flavonoids in relation to neuroprotection in vitro</title><source>Elsevier</source><creator>Pogačnik, Lea ; Pirc, Katja ; Palmela, Inês ; Skrt, Mihaela ; Kwang, Kim S ; Brites, Dora ; Brito, Maria Alexandra ; Ulrih, Nataša Poklar ; Silva, Rui F.M</creator><creatorcontrib>Pogačnik, Lea ; Pirc, Katja ; Palmela, Inês ; Skrt, Mihaela ; Kwang, Kim S ; Brites, Dora ; Brito, Maria Alexandra ; Ulrih, Nataša Poklar ; Silva, Rui F.M</creatorcontrib><description>Abstract Natural food sources constitute a promising source of new compounds with neuroprotective properties, once they have the ability to reach the brain. Our aim was to evaluate the brain accessibility of quercetin, epigallocatechin gallate (EGCG) and cyanidin-3-glucoside (C3G) in relation to their neuroprotective capability. Primary cortical neuron cultures were exposed to oxidative insult in the absence and presence of the selected compounds, and neuroprotection was assessed through evaluation of apoptotic-like and necrotic-like cell death. The brain accessibility of selected compounds was assessed using an optimised human blood-brain barrier model. The blood-brain barrier model was crossed rapidly by EGCG and more slowly by C3G, but not by quercetin. EGCG protected against oxidation-induced neuronal necrotic-like cell death by ~40%, and apoptosis by ~30%. Both quercetin and C3G were less effective, since only the lowest quercetin concentration was protective, and C3G only prevented necrosis by ~37%. Quercetin, EGCG and C3G effectively inhibited α-synuclein fibrillation over the relevant timescale applied here. Overall, EGCG seems to be the most promising neuroprotective compound. Thus, inclusion of this polyphenol in the diet might provide an affordable means to reduce the impact of neurodegenerative diseases.</description><identifier>ISSN: 0006-8993</identifier><identifier>EISSN: 1872-6240</identifier><identifier>DOI: 10.1016/j.brainres.2016.09.020</identifier><identifier>PMID: 27639810</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>alpha-Synuclein - metabolism ; Animals ; Anthocyanins - pharmacokinetics ; Anthocyanins - pharmacology ; Antioxidants - pharmacokinetics ; Antioxidants - pharmacology ; Apoptosis ; Apoptosis - drug effects ; Apoptosis - physiology ; Blood–brain barrier ; Brain - drug effects ; Brain - metabolism ; Catechin - analogs &amp; derivatives ; Catechin - pharmacokinetics ; Catechin - pharmacology ; Cells, Cultured ; Dose-Response Relationship, Drug ; Drug Evaluation, Preclinical ; Drug Stability ; Endothelial Cells - drug effects ; Endothelial Cells - metabolism ; Flavonoids ; Flavonoids - pharmacokinetics ; Flavonoids - pharmacology ; Glucosides - pharmacokinetics ; Glucosides - pharmacology ; Humans ; Necrosis ; Necrosis - drug therapy ; Necrosis - metabolism ; Neurology ; Neurons - drug effects ; Neurons - metabolism ; Neuroprotection ; Neuroprotective Agents - pharmacokinetics ; Neuroprotective Agents - pharmacology ; Oxidative Stress - drug effects ; Oxidative Stress - physiology ; Protein Multimerization - drug effects ; Quercetin - pharmacokinetics ; Quercetin - pharmacology ; Rats, Wistar ; Recombinant Proteins - metabolism ; α-synuclein fibrillation</subject><ispartof>Brain research, 2016-11, Vol.1651, p.17-26</ispartof><rights>2016 Elsevier B.V.</rights><rights>Copyright © 2016 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-61693047c5f4aff0ce49062ceab377a11f13e4bf64c88e2b294d0bf598ce74323</citedby><cites>FETCH-LOGICAL-c456t-61693047c5f4aff0ce49062ceab377a11f13e4bf64c88e2b294d0bf598ce74323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27639810$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pogačnik, Lea</creatorcontrib><creatorcontrib>Pirc, Katja</creatorcontrib><creatorcontrib>Palmela, Inês</creatorcontrib><creatorcontrib>Skrt, Mihaela</creatorcontrib><creatorcontrib>Kwang, Kim S</creatorcontrib><creatorcontrib>Brites, Dora</creatorcontrib><creatorcontrib>Brito, Maria Alexandra</creatorcontrib><creatorcontrib>Ulrih, Nataša Poklar</creatorcontrib><creatorcontrib>Silva, Rui F.M</creatorcontrib><title>Potential for brain accessibility and analysis of stability of selected flavonoids in relation to neuroprotection in vitro</title><title>Brain research</title><addtitle>Brain Res</addtitle><description>Abstract Natural food sources constitute a promising source of new compounds with neuroprotective properties, once they have the ability to reach the brain. Our aim was to evaluate the brain accessibility of quercetin, epigallocatechin gallate (EGCG) and cyanidin-3-glucoside (C3G) in relation to their neuroprotective capability. Primary cortical neuron cultures were exposed to oxidative insult in the absence and presence of the selected compounds, and neuroprotection was assessed through evaluation of apoptotic-like and necrotic-like cell death. The brain accessibility of selected compounds was assessed using an optimised human blood-brain barrier model. The blood-brain barrier model was crossed rapidly by EGCG and more slowly by C3G, but not by quercetin. EGCG protected against oxidation-induced neuronal necrotic-like cell death by ~40%, and apoptosis by ~30%. Both quercetin and C3G were less effective, since only the lowest quercetin concentration was protective, and C3G only prevented necrosis by ~37%. Quercetin, EGCG and C3G effectively inhibited α-synuclein fibrillation over the relevant timescale applied here. Overall, EGCG seems to be the most promising neuroprotective compound. Thus, inclusion of this polyphenol in the diet might provide an affordable means to reduce the impact of neurodegenerative diseases.</description><subject>alpha-Synuclein - metabolism</subject><subject>Animals</subject><subject>Anthocyanins - pharmacokinetics</subject><subject>Anthocyanins - pharmacology</subject><subject>Antioxidants - pharmacokinetics</subject><subject>Antioxidants - pharmacology</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Apoptosis - physiology</subject><subject>Blood–brain barrier</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Catechin - analogs &amp; derivatives</subject><subject>Catechin - pharmacokinetics</subject><subject>Catechin - pharmacology</subject><subject>Cells, Cultured</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Evaluation, Preclinical</subject><subject>Drug Stability</subject><subject>Endothelial Cells - drug effects</subject><subject>Endothelial Cells - metabolism</subject><subject>Flavonoids</subject><subject>Flavonoids - pharmacokinetics</subject><subject>Flavonoids - pharmacology</subject><subject>Glucosides - pharmacokinetics</subject><subject>Glucosides - pharmacology</subject><subject>Humans</subject><subject>Necrosis</subject><subject>Necrosis - drug therapy</subject><subject>Necrosis - metabolism</subject><subject>Neurology</subject><subject>Neurons - drug effects</subject><subject>Neurons - metabolism</subject><subject>Neuroprotection</subject><subject>Neuroprotective Agents - pharmacokinetics</subject><subject>Neuroprotective Agents - pharmacology</subject><subject>Oxidative Stress - drug effects</subject><subject>Oxidative Stress - physiology</subject><subject>Protein Multimerization - drug effects</subject><subject>Quercetin - pharmacokinetics</subject><subject>Quercetin - pharmacology</subject><subject>Rats, Wistar</subject><subject>Recombinant Proteins - metabolism</subject><subject>α-synuclein fibrillation</subject><issn>0006-8993</issn><issn>1872-6240</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqFUU2PFCEQJUbjjqt_YcPRy7QFdNPNxWg260eyiSbqmdB0kTAyzQr0JOOvl56Z9eDFAyFFvXqPeo-QGwYNAybf7JoxGT8nzA2vdQOqAQ5PyIYNPd9K3sJTsgEAuR2UElfkRc67Wgqh4Dm54r0UamCwIb-_xoJz8SZQFxM9kVJjLebsRx98OVIzT_WYcMw-0-hoLubSWQsMaAtO1AVziHP0U6aVIWEwxceZlkhnXFJ8SFXHnp5q--BLii_JM2dCxleX-5r8-HD3_fbT9v7Lx8-37--3tu1k2UomlYC2t51rjXNgsVUguUUzir43jDkmsB2dbO0wIB-5aicYXacGi30ruLgmr8-89Q-_FsxF7322GIKZMS5Zs0H0XHUdhwqVZ6hNMeeETj8kvzfpqBno1Xe904--69V3DUrDafDmorGMe5z-jj0aXQHvzgCsmx48Jp2tx9ni5FP1RU_R_1_j7T8UNvjZWxN-4hHzLi6pplT30Zlr0N_W9NfwmRQg26ETfwAlyq9C</recordid><startdate>20161115</startdate><enddate>20161115</enddate><creator>Pogačnik, Lea</creator><creator>Pirc, Katja</creator><creator>Palmela, Inês</creator><creator>Skrt, Mihaela</creator><creator>Kwang, Kim S</creator><creator>Brites, Dora</creator><creator>Brito, Maria Alexandra</creator><creator>Ulrih, Nataša Poklar</creator><creator>Silva, Rui F.M</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>20161115</creationdate><title>Potential for brain accessibility and analysis of stability of selected flavonoids in relation to neuroprotection in vitro</title><author>Pogačnik, Lea ; Pirc, Katja ; Palmela, Inês ; Skrt, Mihaela ; Kwang, Kim S ; Brites, Dora ; Brito, Maria Alexandra ; Ulrih, Nataša Poklar ; Silva, Rui F.M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-61693047c5f4aff0ce49062ceab377a11f13e4bf64c88e2b294d0bf598ce74323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>alpha-Synuclein - metabolism</topic><topic>Animals</topic><topic>Anthocyanins - pharmacokinetics</topic><topic>Anthocyanins - pharmacology</topic><topic>Antioxidants - pharmacokinetics</topic><topic>Antioxidants - pharmacology</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Apoptosis - physiology</topic><topic>Blood–brain barrier</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Catechin - analogs &amp; derivatives</topic><topic>Catechin - pharmacokinetics</topic><topic>Catechin - pharmacology</topic><topic>Cells, Cultured</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Evaluation, Preclinical</topic><topic>Drug Stability</topic><topic>Endothelial Cells - drug effects</topic><topic>Endothelial Cells - metabolism</topic><topic>Flavonoids</topic><topic>Flavonoids - pharmacokinetics</topic><topic>Flavonoids - pharmacology</topic><topic>Glucosides - pharmacokinetics</topic><topic>Glucosides - pharmacology</topic><topic>Humans</topic><topic>Necrosis</topic><topic>Necrosis - drug therapy</topic><topic>Necrosis - metabolism</topic><topic>Neurology</topic><topic>Neurons - drug effects</topic><topic>Neurons - metabolism</topic><topic>Neuroprotection</topic><topic>Neuroprotective Agents - pharmacokinetics</topic><topic>Neuroprotective Agents - pharmacology</topic><topic>Oxidative Stress - drug effects</topic><topic>Oxidative Stress - physiology</topic><topic>Protein Multimerization - drug effects</topic><topic>Quercetin - pharmacokinetics</topic><topic>Quercetin - pharmacology</topic><topic>Rats, Wistar</topic><topic>Recombinant Proteins - metabolism</topic><topic>α-synuclein fibrillation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pogačnik, Lea</creatorcontrib><creatorcontrib>Pirc, Katja</creatorcontrib><creatorcontrib>Palmela, Inês</creatorcontrib><creatorcontrib>Skrt, Mihaela</creatorcontrib><creatorcontrib>Kwang, Kim S</creatorcontrib><creatorcontrib>Brites, Dora</creatorcontrib><creatorcontrib>Brito, Maria Alexandra</creatorcontrib><creatorcontrib>Ulrih, Nataša Poklar</creatorcontrib><creatorcontrib>Silva, Rui F.M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pogačnik, Lea</au><au>Pirc, Katja</au><au>Palmela, Inês</au><au>Skrt, Mihaela</au><au>Kwang, Kim S</au><au>Brites, Dora</au><au>Brito, Maria Alexandra</au><au>Ulrih, Nataša Poklar</au><au>Silva, Rui F.M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Potential for brain accessibility and analysis of stability of selected flavonoids in relation to neuroprotection in vitro</atitle><jtitle>Brain research</jtitle><addtitle>Brain Res</addtitle><date>2016-11-15</date><risdate>2016</risdate><volume>1651</volume><spage>17</spage><epage>26</epage><pages>17-26</pages><issn>0006-8993</issn><eissn>1872-6240</eissn><abstract>Abstract Natural food sources constitute a promising source of new compounds with neuroprotective properties, once they have the ability to reach the brain. Our aim was to evaluate the brain accessibility of quercetin, epigallocatechin gallate (EGCG) and cyanidin-3-glucoside (C3G) in relation to their neuroprotective capability. Primary cortical neuron cultures were exposed to oxidative insult in the absence and presence of the selected compounds, and neuroprotection was assessed through evaluation of apoptotic-like and necrotic-like cell death. The brain accessibility of selected compounds was assessed using an optimised human blood-brain barrier model. The blood-brain barrier model was crossed rapidly by EGCG and more slowly by C3G, but not by quercetin. EGCG protected against oxidation-induced neuronal necrotic-like cell death by ~40%, and apoptosis by ~30%. Both quercetin and C3G were less effective, since only the lowest quercetin concentration was protective, and C3G only prevented necrosis by ~37%. Quercetin, EGCG and C3G effectively inhibited α-synuclein fibrillation over the relevant timescale applied here. Overall, EGCG seems to be the most promising neuroprotective compound. Thus, inclusion of this polyphenol in the diet might provide an affordable means to reduce the impact of neurodegenerative diseases.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>27639810</pmid><doi>10.1016/j.brainres.2016.09.020</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0006-8993
ispartof Brain research, 2016-11, Vol.1651, p.17-26
issn 0006-8993
1872-6240
language eng
recordid cdi_proquest_miscellaneous_1837295520
source Elsevier
subjects alpha-Synuclein - metabolism
Animals
Anthocyanins - pharmacokinetics
Anthocyanins - pharmacology
Antioxidants - pharmacokinetics
Antioxidants - pharmacology
Apoptosis
Apoptosis - drug effects
Apoptosis - physiology
Blood–brain barrier
Brain - drug effects
Brain - metabolism
Catechin - analogs & derivatives
Catechin - pharmacokinetics
Catechin - pharmacology
Cells, Cultured
Dose-Response Relationship, Drug
Drug Evaluation, Preclinical
Drug Stability
Endothelial Cells - drug effects
Endothelial Cells - metabolism
Flavonoids
Flavonoids - pharmacokinetics
Flavonoids - pharmacology
Glucosides - pharmacokinetics
Glucosides - pharmacology
Humans
Necrosis
Necrosis - drug therapy
Necrosis - metabolism
Neurology
Neurons - drug effects
Neurons - metabolism
Neuroprotection
Neuroprotective Agents - pharmacokinetics
Neuroprotective Agents - pharmacology
Oxidative Stress - drug effects
Oxidative Stress - physiology
Protein Multimerization - drug effects
Quercetin - pharmacokinetics
Quercetin - pharmacology
Rats, Wistar
Recombinant Proteins - metabolism
α-synuclein fibrillation
title Potential for brain accessibility and analysis of stability of selected flavonoids in relation to neuroprotection in vitro
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T18%3A43%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Potential%20for%20brain%20accessibility%20and%20analysis%20of%20stability%20of%20selected%20flavonoids%20in%20relation%20to%20neuroprotection%20in%20vitro&rft.jtitle=Brain%20research&rft.au=Poga%C4%8Dnik,%20Lea&rft.date=2016-11-15&rft.volume=1651&rft.spage=17&rft.epage=26&rft.pages=17-26&rft.issn=0006-8993&rft.eissn=1872-6240&rft_id=info:doi/10.1016/j.brainres.2016.09.020&rft_dat=%3Cproquest_cross%3E1837295520%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c456t-61693047c5f4aff0ce49062ceab377a11f13e4bf64c88e2b294d0bf598ce74323%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1837295520&rft_id=info:pmid/27639810&rfr_iscdi=true